Neurologist
Dr. E.S. (Ellis) van Etten
&width=400&height=400)
Introduction
I am a vascular neurologist and clinical researcher-epidemiologist at the Department of Neurology at LUMC. I trained as a neurologist at LUMC, where I also completed the epidemiology program. My expertise lies in the care and research of both common and rare causes of ischemic strokes and brain hemorrhages.
I specifically focus on cerebral amyloid angiopathy (CAA), a condition in which small blood vessels in the brain are damaged by the accumulation of amyloid protein. I see patients with the hereditary, non-hereditary, and iatrogenic forms of CAA and have expertise in all clinical phenotypes of the disease. My special focus is on improving the diagnosis and treatment of CAA-related inflammation (CAA-ri), a rare and severe complication of CAA.
In addition, I am involved in various national and international studies aimed at expanding our understanding of ischemic strokes and brain hemorrhages and developing effective treatments.
I specifically focus on cerebral amyloid angiopathy (CAA), a condition in which small blood vessels in the brain are damaged by the accumulation of amyloid protein. I see patients with the hereditary, non-hereditary, and iatrogenic forms of CAA and have expertise in all clinical phenotypes of the disease. My special focus is on improving the diagnosis and treatment of CAA-related inflammation (CAA-ri), a rare and severe complication of CAA.
In addition, I am involved in various national and international studies aimed at expanding our understanding of ischemic strokes and brain hemorrhages and developing effective treatments.
Scientific research
My research focuses on CAA, with the aim of improving the diagnosis, prognosis, and treatment of CAA. I began my scientific career at the Stroke Research Center of Massachusetts General Hospital (Harvard University, Boston) with a grant from Alzheimer Nederland, where I investigated radiological markers of CAA.
Alongside my neurology training at LUMC, I conducted research on early detection and clinical outcomes of CAA, which led to my PhD in 2021. Additionally, I specialized in CAA-related inflammation (CAA-ri), developed diagnostic criteria, and established international treatment guidelines.
Since 2023, I have been leading the CAA research group at LUMC, coordinating international studies on the natural course of CAA and the development of treatments, and actively participating in various international committees. In 2024, I received another grant from Alzheimer Nederland to further study CAA-ri.
Alongside my neurology training at LUMC, I conducted research on early detection and clinical outcomes of CAA, which led to my PhD in 2021. Additionally, I specialized in CAA-related inflammation (CAA-ri), developed diagnostic criteria, and established international treatment guidelines.
Since 2023, I have been leading the CAA research group at LUMC, coordinating international studies on the natural course of CAA and the development of treatments, and actively participating in various international committees. In 2024, I received another grant from Alzheimer Nederland to further study CAA-ri.
